BR112018069174A2 - tratamento de prurido urêmico - Google Patents

tratamento de prurido urêmico

Info

Publication number
BR112018069174A2
BR112018069174A2 BR112018069174A BR112018069174A BR112018069174A2 BR 112018069174 A2 BR112018069174 A2 BR 112018069174A2 BR 112018069174 A BR112018069174 A BR 112018069174A BR 112018069174 A BR112018069174 A BR 112018069174A BR 112018069174 A2 BR112018069174 A2 BR 112018069174A2
Authority
BR
Brazil
Prior art keywords
treatment
uremic
itching
uremic itching
patient
Prior art date
Application number
BR112018069174A
Other languages
English (en)
Inventor
Hawi Amale
Good Jennifer
Sciascia Thomas
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of BR112018069174A2 publication Critical patent/BR112018069174A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a presente invenção refere-se a métodos para o tratamento de prurido urêmico com composições antipruriginosas, em que o método fornece um efeito terapêutico em um paciente.
BR112018069174A 2016-03-21 2017-03-21 tratamento de prurido urêmico BR112018069174A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311134P 2016-03-21 2016-03-21
US201662412584P 2016-10-25 2016-10-25
PCT/US2017/023398 WO2017165409A1 (en) 2016-03-21 2017-03-21 Treatment of uremic pruritus

Publications (1)

Publication Number Publication Date
BR112018069174A2 true BR112018069174A2 (pt) 2019-01-29

Family

ID=59899743

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069174A BR112018069174A2 (pt) 2016-03-21 2017-03-21 tratamento de prurido urêmico

Country Status (10)

Country Link
US (1) US20180008592A1 (pt)
EP (1) EP3432871B1 (pt)
JP (2) JP2019509309A (pt)
KR (1) KR20180120756A (pt)
CN (1) CN109310656A (pt)
AU (1) AU2017238051B9 (pt)
BR (1) BR112018069174A2 (pt)
CA (1) CA3017374A1 (pt)
MX (1) MX2018011379A (pt)
WO (1) WO2017165409A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105680A1 (en) * 2018-07-11 2020-01-16 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
WO2021222886A1 (en) * 2020-05-01 2021-11-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods to treat polycystic kidney disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291717C (zh) * 1996-11-25 2006-12-27 东丽株式会社 止痒药物
WO2009047562A1 (en) * 2007-10-08 2009-04-16 Serentis Limited Methods and compositions for the treatment of pruritus
US8686040B2 (en) * 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
KR20150093702A (ko) * 2012-12-14 2015-08-18 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법
AU2015274327A1 (en) * 2014-06-13 2017-01-05 Trevi Therapeutics, Inc. Methods for treating pruritus

Also Published As

Publication number Publication date
EP3432871A1 (en) 2019-01-30
EP3432871B1 (en) 2023-11-15
AU2017238051B2 (en) 2022-10-06
MX2018011379A (es) 2019-06-13
JP2019509309A (ja) 2019-04-04
AU2017238051B9 (en) 2022-11-03
JP2022081640A (ja) 2022-05-31
KR20180120756A (ko) 2018-11-06
CN109310656A (zh) 2019-02-05
CA3017374A1 (en) 2017-09-28
US20180008592A1 (en) 2018-01-11
WO2017165409A1 (en) 2017-09-28
EP3432871A4 (en) 2019-10-30
AU2017238051A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112017007767A2 (pt) canabidiol para uso, método para tratar um paciente que sofre de complexo esclerose tuberosa, e, composição.
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
PH12015502075B1 (en) Treatment of cataplexy
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
BR112018069174A2 (pt) tratamento de prurido urêmico
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
BR112015022513A2 (pt) produto e método para tratamento de diarreia
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2767 DE 16-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.